You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

France: These 8 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in France

Generic Entry Dates in Other Countries

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: France: These 8 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Tradename Ingredient Estimated Entry Opportunity Date
CORLANOR ivabradine hydrochloride 2025-02-28
CORLANOR ivabradine 2025-02-28
KOSELUGO selumetinib sulfate 2025-12-21
LATUDA lurasidone hydrochloride 2025-05-26
VIZIMPRO dacomitinib 2024-05-06
>Tradename >Ingredient >Estimated Entry Opportunity Date

Details: France: These 8 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: France Patent 2,882,553

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: France Patent 2,882,555

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can KOSELUGO (selumetinib sulfate) generic drug versions launch?

Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2025
Generic Entry Controlled by: France Patent 21C1051

KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.

This drug has one hundred and ninety-eight patent family members in forty-four countries.

See drug price trends for KOSELUGO.

The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2025
Generic Entry Controlled by: France Patent 14C0069

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-eight patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: France Patent 19C1052

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can NEURACEQ (florbetaben f-18) generic drug versions launch?

Generic name: florbetaben f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 17, 2024
Generic Entry Controlled by: France Patent 15C0012

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: France Patent 20C1024

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: France Patent 14C0041

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: France Patent 20C1024

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and twenty-five patent family members in thirty-three countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.